Skip to content

Reflexology's Effect on Polycystic Ovary Syndrome: A Pilot Study

Reflexology's Effect on Polycystic Ovary Syndrome (REPOS): A Pilot Study

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00746148
Acronym
REPOS
Enrollment
140
Registered
2008-09-03
Start date
2012-12-31
Completion date
2013-12-31
Last updated
2012-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome

Keywords

Polycystic Ovary Syndrome, Reflexology, Complementary and Alternative Medicine, Endocrinopathy, Oligo, Amenorrhoea

Brief summary

Polycystic Ovary Syndrome (PCOS) is very common, affecting approximately 5% of women of reproductive age, and impacts not only on quality of life, but also has long-term health consequences for many sufferers, such as increased risks of developing Type II diabetes, cardiovascular disease and cancer of the womb. The symptoms that may occur such as irregular periods; lots of body hair; thinning hair on scalp, obesity and infertility, can also lead to poor self-esteem. Whilst treatments can help fertility, other treatments to correct the other symptoms are less successful. Alternative methods to regulate periods would be helpful, especially ones which avoid the long-term use of steroids in patients who may already be overweight. Reflexology is poorly represented in scientific papers, with nothing published regarding reflexology and its effect upon PCOS. However patients who use reflexology report more regular periods, thicker hair on scalp and greater wellbeing. Therefore we aim to investigate the effect of reflexology on: 1. The menstruation cycle (normal being every 21-35 days). 2. Imbalances in hormone, insulin and blood sugar levels associated with PCOS. 3. Other problems associated with PCOS such as thinning hair on scalp, excessive body hair, and obesity. 4. Quality of life. Government and NHS agendas agree that if there's evidence of an effective complimentary therapy the NHS should provide it. Therefore the results may have an influence on the care pathways of patients with PCOS towards a more holistic, patient centred and empowered approach. It is also non invasive and liable to result in higher patient satisfaction regarding their treatment. This research may also inform policy makers so that complementary medicine provision is provided on a wider basis within the NHS, which at the moment is dictated by the individual Trust's budget allocation. However this research could save money overall as in America, the yearly cost of treating PCOS is $4.36 billion.

Interventions

OTHERReflexology

10 weekly sessions of 45 minutes each

Sponsors

University of Nottingham
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 38 Years
Healthy volunteers
No

Inclusion criteria

* Women with PCOS

Exclusion criteria

* use of complimentary therapies within 6/12 prior to recruitment * BMI \>35 * taken combined oral contraceptives, metformin, or cyclical progestogens within 3/12 prior to recruitment

Design outcomes

Primary

MeasureTime frame
To identify the most appropriate primary outcome measure for the ensuing RCTWeek 30

Secondary

MeasureTime frame
Attainment of normal menstrual cycle length (i.e. 21-35 days)1 (baseline), week 10 (end of treatment) and week 30 (end of study)
Hormonal imbalances and irregular menses (commonly regarded at 6 cycles per annum or less)1 (baseline), week 10 (end of treatment) and week 30 (end of study)
weight, body mass index (BMI), hirsutism, thinning hairweek 1 (baseline), week 10 (end of treatment) and week 30 (end of study)
Fasting Insulin and blood sugar levelsweek 1 (baseline), week 10 (end of treatment) and week 30 (end of study)
Quality of Lifeweek 1 (baseline), week 10 (end of treatment) and week 30 (end of study)

Countries

United Kingdom

Contacts

Primary ContactDawn-Marie Walker, Phd
dawn-marie.walker@nottingham.ac.uk+44 (0)115 82 30511

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026